ArticleAmerican journal of cancer research2014
Histone/protein deacetylase SIRT1 is an anticancer therapeutic target.
Article in American journal of cancer research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 18 citations in OpenAlex.
- Dissecting the epigenetic orchestra of HDAC isoforms in breast cancer development: a review.Medical oncology (Northwood, London, England) · 2024Review
- DCAF2 regulates the proliferation and differentiation of mouse progenitor spermatogonia by targeting p21 and thymine DNA glycosylase.Cell proliferation · 2024Article
- Rapamycin suppresses the PI3K/AKT/mTOR signaling pathway by targetingExperimental and therapeutic medicine · 2021Article
- SIRT1 promotes formation of breast cancer through modulating Akt activity.Journal of Cancer · 2018Article
- Proteomic Analysis of Combined Gemcitabine and Birinapant in Pancreatic Cancer Cells.Frontiers in pharmacology · 2018Article
- HuR silencing elicits oxidative stress and DNA damage and sensitizes human triple-negative breast cancer cells to radiotherapy.Oncotarget · 2016Article
- SIRT1 induces tumor invasion by targeting epithelial mesenchymal transition-related pathway and is a prognostic marker in triple negative breast cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- [SIRT1 Influences the Sensitivity of A549 Non-small Cell Lung Cancer Cell Line to Cisplatin via Modulating the Noxa Expression].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2016Article
- Metal-binding effects of sirtuin inhibitor sirtinol.Supramolecular chemistry · 2016Article
- miR-34a inhibits cell proliferation in prostate cancer by downregulation of SIRT1 expression.Oncology letters · 2015Article
- Higher expression of SIRT1 induced resistance of esophageal squamous cell carcinoma cells to cisplatin.Journal of thoracic disease · 2015Article
- Sirtuin inhibitor sirtinol is an intracellular iron chelator.Chemical communications (Cambridge, England) · 2015Article
- Gambogic Acid lysinate induces apoptosis in breast cancer mcf-7 cells by increasing reactive oxygen species.Evidence-based complementary and alternative medicine : eCAM · 2015Article
- Clinicopathological and prognostic role of SIRT1 in breast cancer patients: a meta-analysis.International journal of clinical and experimental medicine · 2015Article
- SIRT1 counteracted the activation of STAT3 and NF-κB to repress the gastric cancer growth.International journal of clinical and experimental medicine · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
SIRT1, a member of the NAD(+)-dependent histone/protein deacetylase family, is involved in chromatin remodeling, DNA repair, and stress response and is a potential drug target. 5-fluorouracil (FU) and the SN1-type DNA methylating agent temozolomide (TMZ) are anticancer agents. In this study, we demonstrate that sirt1 knockout mouse embryonic fibroblast cells are more sensitive to FU and DNA methylating agents than normal cells. Based on these findings, the chemotherapy efficacy of SIRT1 inhibitors in combination with FU or TMZ were tested with human breast cancer cells. We found that treatments combining SIRT1 inhibitors with FU or TMZ show synergistic reduction of cell viability and colony formation of breast cancer cells. Thus, inhibition of SIRT1 activity provides a novel anticancer strategy.
Indexed as
Identifiers
24959376PMC4065402W59701332What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.